94 related articles for article (PubMed ID: 17968028)
1. Functional outcomes in the treatment of adults with ADHD.
Adler LA; Spencer TJ; Levine LR; Ramsey JL; Tamura R; Kelsey D; Ball SG; Allen AJ; Biederman J
J Atten Disord; 2008 May; 11(6):720-7. PubMed ID: 17968028
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
Allen AJ; Kurlan RM; Gilbert DL; Coffey BJ; Linder SL; Lewis DW; Winner PK; Dunn DW; Dure LS; Sallee FR; Milton DR; Mintz MI; Ricardi RK; Erenberg G; Layton LL; Feldman PD; Kelsey DK; Spencer TJ
Neurology; 2005 Dec; 65(12):1941-9. PubMed ID: 16380617
[TBL] [Abstract][Full Text] [Related]
6. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
Spencer TJ; Sallee FR; Gilbert DL; Dunn DW; McCracken JT; Coffey BJ; Budman CL; Ricardi RK; Leonard HL; Allen AJ; Milton DR; Feldman PD; Kelsey DK; Geller DA; Linder SL; Lewis DW; Winner PK; Kurlan RM; Mintz M
J Atten Disord; 2008 Jan; 11(4):470-81. PubMed ID: 17934184
[TBL] [Abstract][Full Text] [Related]
9. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
Buitelaar JK; Wilens TE; Zhang S; Ning Y; Feldman PD
J Child Psychol Psychiatry; 2009 Mar; 50(3):335-42. PubMed ID: 19309330
[TBL] [Abstract][Full Text] [Related]
10. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder.
Weiss MD; Gibbins C; Goodman DW; Hodgkins PS; Landgraf JM; Faraone SV
J Clin Psychiatry; 2010 Apr; 71(4):381-90. PubMed ID: 20361900
[TBL] [Abstract][Full Text] [Related]
11. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
[TBL] [Abstract][Full Text] [Related]
13. The reliability and validity of self- and investigator ratings of ADHD in adults.
Adler LA; Faraone SV; Spencer TJ; Michelson D; Reimherr FW; Glatt SJ; Marchant BK; Biederman J
J Atten Disord; 2008 May; 11(6):711-9. PubMed ID: 18025250
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
Brown RT; Perwien A; Faries DE; Kratochvil CJ; Vaughan BS
Clin Pediatr (Phila); 2006 Nov; 45(9):819-27. PubMed ID: 17041169
[TBL] [Abstract][Full Text] [Related]
16. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
Biederman J; Pliszka SR
J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
18. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Adler LA; Spencer TJ; Williams DW; Moore RJ; Michelson D
J Atten Disord; 2008 Nov; 12(3):248-53. PubMed ID: 18448861
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
